Will dogs’ longevity become a scientific reality? Researchers test anti-ageing drugs
– Scientists are studying experimental drugs that aim to slow down some of the ageing processes in dogs and enable them to live longer and in better health, according to “Science Focus”.
Two of the main studies are examining compounds that affect the metabolism and the biological mechanisms of ageing.
They are being assessed through clinical studies, which must determine whether the benefits are real and whether their use is safe.
One of the treatment candidates is called LOY-002 and is being produced by the American company “Loyal”.
The drug targets elderly dogs and focuses on the metabolic changes that occur with advancing age.
According to the company, the aim is to improve the way the body processes insulin and to delay the appearance of some health problems linked to ageing.
To assess its effects, the company is conducting the “STAY” study, in which around 1,300 dogs at more than 70 veterinary clinics in the United States of America are included.
The study is placebo-controlled: some dogs receive the experimental drug, while others receive a tablet without the active ingredient.
Neither the owners nor the researchers know during the study which dogs receive the drug and which receive the “placebo”, a method that helps reduce bias when assessing the results.
According to “Loyal”, the U.S. Food and Drug Administration (FDA) has accepted the safety data for LOY-002 for its intended use.
This is a step in the assessment process, but it does not mean the drug has received final approval for general use.
The study must provide further data on its safety and effectiveness.
Another study is examining rapamycin, a drug that affects the immune system and the metabolism.
Studies in mice have shown that this substance can extend lifespan, but it is not clear whether it will have the same effect in dogs.
The “TRIAD” study, linked to the “Dog Aging Project” research project and Tufts University, in the state of Massachusetts, USA, aims to determine whether rapamycin can extend dogs’ lives and improve health indicators during ageing.
According to the protocol published by the university, participating dogs are randomly assigned to receive rapamycin or a “placebo”.
The planned treatment lasts one year, while health follow-up continues for a longer period.
The researchers will assess various health indicators, including heart function and changes that may be linked to ageing.
The aim is to determine whether the possible benefits are measurable and whether they are accompanied by risks.
Why is this research important?
Dogs age faster than humans and can develop age-related diseases, such as heart problems, tumours and a decline in physical functions.
The researchers hope that interventions that affect the biological processes of ageing will help preserve health for longer, not simply treat one particular disease.
However, longevity and health are not the same thing.
A treatment may improve some health indicators without proving that it extends life.
For this reason, the results must be measured in controlled studies and over a sufficient period. /



Komentet
Bëhu i pari që komenton!
Lini një Koment të Ri
Për t'u përgjigjur një komenti specifik, kliko butonin 💬 Përgjigju poshtë atij komenti.